孤立性与系统性心脏结节病的FDG摄取模式
回顾性分析31例孤立性心脏结节病(ICS)与91例系统性心脏结节病(SCS)患者治疗前后的FDG-PET/CT,比较两组治疗反应与预后。SCS组右心室受累更常见且SUVmax、CMV、CMA更高,但两组治疗反应、复发率及主要不良心脏事件(MACE)发生率无显著差异。
要点
- SCS组右心室受累比例显著高于ICS组(44.0% vs 9.6%,p < .001)。
- SCS组SUVmax、CMV、CMA均显著高于ICS组(p < .001)。
- 两组治疗反应相似,复发率与MACE发生率均无显著差异。
核心结论
- SCS患者治疗前心脏结节病病灶较ICS患者更活跃、范围更广,但两组治疗反应与预后相似。
研究设计与样本
- 回顾性分析31例ICS与91例SCS患者治疗前后的FDG-PET/CT图像,其中16例ICS与35例SCS接受了超过2年的治疗并评估治疗反应、复发及MACE。
主要发现
- 局灶性摄取模式在ICS组(74.2%)与SCS组(63.7%)中均较局灶叠加弥漫性摄取模式更常见。
- SCS组右心室受累显著多于ICS组(44.0% vs 9.6%,p < .001)。
- SCS组SUVmax(9.1 ± 4.1 vs 4.8 ± 2.1)、CMV(118.0 ± 111.3 ml vs 68.3 ± 94.7 ml)、CMA(541.6 ± 578.7 MBq vs 265.1 ± 396.0 MBq)均显著高于ICS组(p < .001)。
- 免疫抑制治疗后心脏摄取完全消退在ICS组为62.5%、SCS组为77.1%,两组无显著差异。
- 复发率(ICS组40.0% vs SCS组44.4%)与MACE发生率(ICS组25.0% vs SCS组22.8%)均无显著差异。
关键数值与推荐
- 局灶性摄取模式:ICS组74.2%,SCS组63.7%。
- 右心室受累:ICS组9.6% vs SCS组44.0%(p < .001)。
- SUVmax:ICS组4.8 ± 2.1 vs SCS组9.1 ± 4.1(p < .001)。
- CMV:ICS组68.3 ± 94.7 ml vs SCS组118.0 ± 111.3 ml(p < .001)。
- CMA:ICS组265.1 ± 396.0 MBq vs SCS组541.6 ± 578.7 MBq(p < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We aimed to investigate the pre-treatment characteristics and treatment responses of isolated and systemic cardiac sarcoidosis (ICS and SCS) from FDG-PET/CT studies and to compare the prognoses of the two groups. METHODS: FDG-PET/CT images taken before and after treatment of 31 ICS and 91 SCS patients were analyzed retrospectively. Treatment response and recurrence were determined from the course of FDG-PET/CT. Treatment response and the incidence of both recurrence and major adverse cardiac events (MACE) were assessed in 16 ICS and 35 SCS patients who had been treated for more than 2 years. RESULTS: A focal uptake pattern was more often observed than a focal-on-diffuse uptake pattern in both the ICS (74.2%) and SCS (63.7%) groups. Right ventricular involvement was significantly more frequent in SCS than ICS (44.0% vs. 9.6%, p < .001). SUVmax, cardiac metabolic volume (CMV), and cardiac metabolic activity (CMA) were significantly higher in SCS than ICS (SUVmax, 9.1 ± 4.1 vs. 4.8 ± 2.1; CMV, 118.0 ± 111.3 ml vs. 68.3 ± 94.7 ml; CMA, 541.6 ± 578.7 MBq vs. 265.1 ± 396.0 MBq, p < .001). Treatment responses in the two groups were similar, and complete resolution of cardiac uptake after immunosuppressive treatment was obtained in 62.5% of ICS patients and 77.1% of SCS patients (not significantly different). Likewise, no significant difference was found in the incidence of recurrence (40.0% for ICS, 44.4% for SCS) or MACE (25.0% for ICS, 22.8% for SCS). CONCLUSION: SCS patients had more active and extensive CS lesions than ICS patients before treatment, but the two groups showed similar treatment responses and prognoses.
引用
- Kaneko K, Nagao M, Yamamoto A, et al. FDG uptake patterns in isolated and systemic cardiac sarcoidosis. J Nucl Cardiol. 2022. PMID: 36192524. doi:10.1007/s12350-022-03106-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。